PubMed Health⌕ Search

PubMed · 10719596

[In Process Citation]

Abstract

A main basis of this habilitation thesis is the development of a portable, mains-free measurement device for determining breath ethanol concentrations (BrEC) both during spontaneous breathing and in mechanically ventilated patinets undergoing inhalation anaesthesia, for detecting and quantifying irrigation fluid absorbed during endourological surgical interventions. Here a respired gas has to be measured which compared to other usually measured gases 1) is present in substatially smaller concentrations, 2) is subject to significant influences by temperature and humidity in the expired air, and 3) can only be measured discontinuously in the alveolar air due to technical limitations of the sensor. The basis for investigating accuracy of measurement was not just evaluation of the device using different lung models, but also a comparison with the target parameter "absorbed irrigation fluid" using another further-developed reference procedure, i.e. direct measurement of sorbitol and mannitol concentrations in serum. This has the added advantage that even when ethanol monitoring is not available, another laboratory procedure is indeed available for directly evaluating the absorption of irrigation fluid. In the clinical aspects of this thesis, ethanol monitoring helped show that during transurethral resection of the prostate (TURP) in spontaneously breathing patients undergoing regional anaesthesia, irrigation fluid was intravascularly absorbed not more often, but more rapidly and in larger quantities than it was in mechanically ventilated patients undergoing inhalation anaesthesia. A possible reason for this was the significantly reduced central venous pressure observed in the group of patients undergoing regional anaesthesia. The diagnosis of a delayed extravascular absorption of irrigation fluid during percutaneous nephrolithotripsy (PNL), made with the assistance of the ethanol monitoring, was associated with a significantly prolonged period of hospitalization in the clinic and an increase in opioid requirements. This finding can be explained pathophysiologically by an increased trauma to the kidney with injury to bordering organ structures. As a result of close co-operation with several departments of the Medical University of Lubeck, we now have at our disposal an excellent BrEC-measuring device for detecting and quantifying absorbed irrigation fluid during urosurgical procedures. The results of the clinical studies presented here underscore the value of the newly-developed AlcoMed 3011.

Explore related subjects

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

H Gehring. 2000. [In Process Citation]. https://doi.org/10.1055/s-2000-235

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

Effectiveness of high-dose versus standard-dose influenza vaccines against hospitalisation according to frailty risk: a prespecified analysis of the randomised trial DANFLU-2.

BACKGROUND: Frailty is a major risk factor for influenza-related complications and can influence vaccine effectiveness. We aimed to assess the relative vaccine effectiveness (rVE) of high-dose (HD-IIV) versus standard-dose inactivated influenza vaccine (SD-IIV) in older adults aged 65 years or older according to frailty risk. METHODS: This study was a prespecified analysis of DANFLU-2, an open-label, individually randomised trial, conducted in Denmark during three consecutive influenza seasons (2022-23, 2023-24, and 2024-25). Adults aged 65 years or older were randomised (1:1) to the HD-IIV or SD-IIV group. The primary endpoint was hospitalisation for influenza or pneumonia. Frailty was defined according to the validated Hospital Frailty Risk Score (HFRS) based on ICD-10 codes within 10 years before randomisation. Participants were stratified into three HFRS categories, namely low (<5 points), intermediate (5-15 points), and high (>15 points) frailty risk. The rVE of HD-IIV versus SD-IIV against the primary endpoint was assessed across prespecified HFRS categories and treating HFRS as a continuous variable. Pearson's chi-square test was used to compare safety events across frailty risk groups and randomisation groups. FINDINGS: Among 332&#x2009;438 randomised participants (mean age 73&#xb7;7 years [SD 5&#xb7;8]; 161&#x2009;538 [48&#xb7;6%] were female), 276&#x2009;173 (83&#xb7;1%) had low frailty risk, 52&#x2009;395 (15&#xb7;8%) had intermediate frailty risk, and 3861 (1&#xb7;2%) had high frailty risk. The primary endpoint of hospitalisation for influenza or pneumonia occurred in 1424 (0&#xb7;5%) of 276&#x2009;173 participants with low frailty risk, 761 (1&#xb7;5%) of 52&#x2009;395 with intermediate frailty risk, and 163 (4&#xb7;2%) of 3861 with high frailty risk (relative risk [RR] for intermediate vs low frailty risk 2&#xb7;8 [95% CI 2&#xb7;6-3&#xb7;1]; RR for high vs low frailty risk 8&#xb7;2 [7&#xb7;0-9&#xb7;6]). HFRS as a continuous variable significantly modified the effect of HD-IIV versus SD-IIV against the primary endpoint with higher rVE estimates with increasing HFRS (pinteraction=0&#xb7;020). The rVE was 0&#xb7;2% (95% CI -10&#xb7;8 to 10&#xb7;2) among those with low frailty risk, 13&#xb7;1% (-0&#xb7;4 to 24&#xb7;8) among those with intermediate frailty risk, and 19&#xb7;9% (-10&#xb7;3 to 42&#xb7;1) among those with high frailty risk. No significant interaction was observed when HFRS was assessed according to the prespecified categorical frailty groups (pinteraction=0&#xb7;17). The proportion of participants with at least one serious adverse event increased across frailty risk groups (13&#x2009;366 [4&#xb7;8%] of 275&#x2009;795 for low frailty risk, 5475 [10&#xb7;5%] of 52&#x2009;315 for intermediate frailty risk, and 777 [20&#xb7;2%] of 3850 for high frailty risk; p<0&#xb7;0001), with similar proportions of serious adverse events in the HD-IIV and SD-IIV groups for each frailty risk group. INTERPRETATION: Among adults aged 65 years or older in Denmark, frailty risk might modify the effects of HD-IIV versus SD-IIV against hospitalisation for influenza or pneumonia, with higher rVE estimates with increasing frailty risk. These findings might support considering high-dose influenza vaccines for frail older adults. However, effect modification was not evident when frailty was assessed using prespecified categorical subgroups, and subgroup-specific estimates were imprecise, with 95% CIs crossing the null. These results should be considered exploratory, warranting further investigation. FUNDING: The DANFLU-2 trial was funded by Sanofi.

Journal Article↗